Last Updated : January 10, 2017
Details
FilesGeneric Name:
Venetoclax
Project Status:
Withdrawn
Manufacturer:
AbbVie Corporation
Brand Name:
Venclexta
Project Line:
Reimbursement Review
Project Number:
PC0087-000
Strength:
10 mg, 50 mg & 100 mg tablets
Tumour Type:
Leukemia
Indications:
Chronic Lymphocytic Leukemia (with 17p deletion)
Funding Request:
For the treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy and have a 17p deletion
Review Status:
Withdrawn
Pre Noc Submission:
Yes
Sponsor:
AbbVie Corporation
Submission Date:
Submission Deemed Complete:
Prioritization Requested:
Requested and Not Granted
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Clarification:
AbbVie Corporation requested a voluntary withdrawal of the pCODR 10087 Venetoclax (Venclexta) for CLL Submission. As per pCODR Procedures B3.1.6.2 b), the pCODR Provincial Advisory Group has agreed to the request to withdraw and decided to not continue the review as a PAG Submission. Please note that as per pCODR Procedures, Section B.6.2, if a submission is withdrawn but a pERC Initial Recommendation has been made, the pCODR program will continue to publically post the pERC Initial Recommendation.
pERC Meeting:
Files
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.
Last Updated : January 10, 2017